Cargando…

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

BACKGROUND: There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs. METHODS: Patients with uUTI were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dunne, Michael W, Aronin, Steven I, Das, Anita F, Akinapelli, Karthik, Zelasky, Michael T, Puttagunta, Sailaja, Boucher, Helen W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825825/ https://www.ncbi.nlm.nih.gov/pubmed/36069202 http://dx.doi.org/10.1093/cid/ciac738

Ejemplares similares

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections
por: Dunne, Michael W, et al.
Publicado: (2023)

1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection
por: Puttagunta, Sailaja, et al.
Publicado: (2018)

Applying Desirability of Outcome Ranking End Points
por: Dunne, Michael W, et al.
Publicado: (2023)

1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
por: Dunne, Michael, et al.
Publicado: (2018)

1232. Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
por: Aronin, Steven I, et al.
Publicado: (2023)

1724. Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
por: Puttagunta, Sailaja, et al.
Publicado: (2022)

Correction to: Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Publicado: (2023)

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
por: Puttagunta, Sailaja, et al.
Publicado: (2023)

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
por: Maher, Joshua M, et al.
Publicado: (2023)

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
por: Dunne, Michael W., et al.
Publicado: (2022)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection
por: Rappo, Urania, et al.
Publicado: (2020)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

An Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary Tract Infections
por: Durkin, Michael J, et al.
Publicado: (2018)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
por: Dunne, Michael, et al.
Publicado: (2018)

Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002–2011
por: Kobayashi, Miwako, et al.
Publicado: (2016)

Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females
por: Yetsko, Aidan, et al.
Publicado: (2023)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

Multidrug Resistance of Escherichia coli From Outpatient Uncomplicated Urinary Tract Infections in a Large United States Integrated Healthcare Organization
por: Ku, Jennifer H, et al.
Publicado: (2023)

Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - Results of a randomized controlled pilot trial
por: Bleidorn, Jutta, et al.
Publicado: (2010)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
por: Rappo, Urania, et al.
Publicado: (2018)

Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial( )
por: ten Doesschate, Thijs, et al.
Publicado: (2021)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Impact of the 2019 Food and Drug Administration Guidance for Uncomplicated Urinary Tract Infection on Treatment Response Rates: A Reanalysis of a Clinical Trial of Nitrofurantoin vs Fosfomycin
por: Grant, Rebecca, et al.
Publicado: (2023)

Efficacy of Single Dose of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary Tract Infection
por: Hassan, Muhammad Mujeeb, et al.
Publicado: (2022)

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015)

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales
por: Lodise, Thomas P, et al.
Publicado: (2021)

Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials
por: Portsmouth, Simon, et al.
Publicado: (2021)

A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
por: Howard-Anderson, Jessica, et al.
Publicado: (2022)

241. Rural-urban differences in antibiotic prescribing for uncomplicated urinary tract infections
por: Clark, Abbye W, et al.
Publicado: (2020)

Psychosocial burden of recurrent uncomplicated urinary tract infections
por: Naber, Kurt G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_duhur9f0sbjupdd0l4gt9vu9ia